Trial Profile
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects With Chronic Allergic Contact Dermatitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Daniluromer (Primary)
- Indications Allergic contact dermatitis
- Focus Therapeutic Use
- Sponsors Edesa Biotech
- 17 Feb 2023 According to the Edesa Biotech media release, the company is preparing for an End of Phase 2 meeting with FDA following full analysis and expects to complete the analysis by mid year.
- 17 Jan 2023 Topline results published in an Edesa Biotech Media Release.
- 16 Dec 2022 According to the Edesa Biotech media release, the company expects to report topline data in the next four weeks.